← SynDRA
BRILANESTRANT
SynDRA canonical compound SYN0038319 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | ESR1 |
|---|
| Mechanism of action | selective estrogen receptor destabilizer |
|---|
All known targets
Mechanisms of action (all sources)
- ESR1 DEGRADER
- selective estrogen receptor destabilizer
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SLC6A3
- NR3C1
- CYP2C19
- CYP2C8
- CYP2C9
- ESR2
- ABL1
- FGFR2
- PGR
- NR3C2
- MAPK1
- KCNH2
- HDAC6
- GSK3B
- CYP3A4
- AR
- CYP2D6
- CYP1A2
- CSNK1D
- CDK2
- BRPF1
- BRD4
- AURKA
- TRIM24
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- GPX4
- KSYK
- NSD2
- NTM1A
- NTMT1
- SYK
Cross-references
Synonyms
- GDC-0810
- ARN-810
- RG-6046
- RG6046
- GDC 0810
- ARN 810
- 9MM2R1A06R
- brilanestrantum
- RefChem:917568
- SERD ARN-810
- DTXCID901766125
- RO7056118
- Brilanestrant [USAN]
- UNII-9MM2R1A06R
- GDC0810
- Gdc-0810 (arn-810)
- Brilanestrant; ARN-810
- BRILANESTRANT [INN]
- Brilanestrant (USAN/INN)
- Brilanestrant (GDC-0810)
- SCHEMBL766995
- BRILANESTRANT [WHO-DD]
- orb1302074
- SCHEMBL29356277
- SCHEMBL29423494
- BURHGPHDEVGCEZ-KJGLQBJMSA-N
- GLXC-10829
- EX-A2378
- BDBM50090462
- MFCD28902190
- NSC787326
- s7855
- AKOS025404916
- CCG-269201
- CS-4588
- EBC-373073
- NSC-787326
- GDC-0810; Brilanestrant; ARN-810
- NCGC00509938-01
Look up BRILANESTRANT in the interactive SynDRA portal →